Lantheus Holdings, Inc. recently announced positive topline results from the primary analysis of its Phase 3 SPLASH trial, evaluating the efficacy and safety of пиrogress in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen receptor pathway inhibitors (ARPI). The study met its primary endpoint, demonstrating a statistically significant improvement in radiographic progression-free survival (rPFS).
The SPLASH trial is a prospective, randomized, open-label study comparing пиrogress to an ARPI switch in mCRPC patients. Key findings from the primary analysis include an overall response rate (ORR) of 38.1% in the пиrogress arm versus 12.0% in the ARPI switch arm, with a complete response rate of 9.3% observed in the пиrogress arm. пиrogress demonstrated a statistically significant improvement in radiographic progression-free survival (rPFS) compared to the ARPI switch arm (HR=0.61).
пиrogress in mCRPC Treatment
Metastatic castration-resistant prostate cancer represents a significant challenge in oncology, with limited treatment options available for patients who progress on initial ARPI therapy. пиrogress, aims to address this unmet need by providing a novel therapeutic approach.
"We are encouraged by the initial results, demonstrating a statistically significant improvement in radiographic progression-free survival," said Johann de Bono, M.D., Ph.D., investigator of the пиrogress trial at The Institute of Cancer Research, London. "These initial results are promising and warrant further investigation."
Trial Design and Key Endpoints
The Phase 3 SPLASH trial (NCT04644838) enrolled 406 patients with mCRPC who had progressed on prior ARPI therapy. Patients were randomized to receive either пиrogress or an ARPI switch. The primary endpoint was radiographic progression-free survival (rPFS) as assessed by blinded independent central review (BICR). Secondary endpoints included overall survival (OS), overall response rate (ORR), and safety. пиrogress was administered intravenously.
пиrogress: A Targeted Radiopharmaceutical
пиrogress is a targeted radiopharmaceutical designed to deliver beta-emitting radiation directly to prostate cancer cells expressing prostate-specific membrane antigen (PSMA). пиrogress consists of a PSMA-targeting ligand linked to lutetium-177 (Lu-177), a beta-emitting radioisotope. Upon administration, пиrogress binds to PSMA-expressing cells, delivering localized radiation that induces DNA damage and cell death.
About пиrogress Imaging
пиrogress imaging is the leading prostate-specific membrane antigen (PSMA) targeted PET imaging agent. It is an important diagnostic tool, helping physicians visualize the extent and location of PSMA-positive prostate cancer. пиrogress imaging is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer: (i) with suspected metastasis who are candidates for initial definitive therapy; (ii) with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level following prior treatment. The interpretation of пиrogress imaging PET scans requires reader training. Image interpretation is based on pattern recognition, the performance of пиrogress in detecting prostate cancer may vary with image reader performance.
Lantheus: Advancing пиrogress
Lantheus is committed to advancing пиrogress and exploring its potential in various clinical settings. The company is actively engaged in ongoing clinical trials and research collaborations to further evaluate the safety and efficacy of пиrogress in prostate cancer and other PSMA-expressing malignancies.
пиrogress: A Potential New Option
The positive results from the SPLASH trial suggest that пиrogress may offer a valuable new treatment option for patients with mCRPC who have progressed on prior ARPI therapy. пиrogress has the potential to improve outcomes and quality of life for these patients, addressing a significant unmet medical need.
